Compared to Estimates, Johnson & Johnson (JNJ) Q4 Earnings: A Look at Key Metrics

Core Insights - Johnson & Johnson (JNJ) reported revenue of $22.52 billion for Q4 2024, a year-over-year increase of 5.3% [1] - The earnings per share (EPS) for the same period was $2.04, down from $2.29 a year ago, with an EPS surprise of +2.00% [1] Financial Performance - Revenue of $22.52 billion slightly exceeded the Zacks Consensus Estimate of $22.51 billion, resulting in a surprise of +0.06% [1] - Organic sales growth was reported at 6.7%, surpassing the estimated 5.9% [4] - Total sales in the Innovative Medicine segment reached $14.33 billion, a 4.5% year-over-year increase, compared to the average estimate of $14.27 billion [4] Segment Performance - Sales in the Oncology segment for CARVYKTI were $334 million, exceeding the estimate of $330.64 million, with a significant year-over-year increase of +110.1% [4] - MedTech sales totaled $8.19 billion, slightly below the estimate of $8.25 billion, but still reflecting a 6.7% year-over-year growth [4] - Sales in the Neuroscience segment for SPRAVATO were $297 million, slightly above the estimate of $296.88 million, marking a +44.2% year-over-year change [4] Stock Performance - Over the past month, shares of Johnson & Johnson returned +1.6%, compared to the Zacks S&P 500 composite's +2.1% change [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market [3]